Bioinformatics Market Report 2026

The bioinformatics market size has grown rapidly in recent years. It will grow from $18.54 billion in 2025 to $21.36 billion in 2026 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to expansion of genomic research initiatives, growth in sequencing data volumes, rising demand for computational biology tools, increased use of bioinformatics in drug discovery, availability of advanced data analysis platforms.

The bioinformatics market size is expected to see rapid growth in the next few years. It will grow to $36.99 billion in 2030 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to increasing investments in precision medicine programs, rising adoption of ai-based biological data interpretation, expansion of population genomics studies, growing demand for scalable bioinformatics solutions, increased focus on data security and compliance. Major trends in the forecast period include increasing adoption of AI-driven genomic analysis tools, rising use of cloud-based bioinformatics platforms, growing integration of multi-omics data analysis, expansion of high-throughput data processing capabilities, enhanced focus on data interoperability and sharing.

The expanding pharmaceutical industry is anticipated to drive the growth of the bioinformatics market in the coming years. The pharmaceutical industry encompasses the discovery, development, and production of drugs and medicines by both governmental and private organizations. Bioinformatics is widely applied in the pharmaceutical sector to accelerate drug discovery and development, lower costs, and enhance the efficacy and safety of therapies. For example, in November 2024, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association, reported that North America accounted for 54.8% of estimated global pharmaceutical sales in 2024, compared with 22.7% for Europe. Consequently, the growth of the pharmaceutical industry is fueling the expansion of the bioinformatics market.

Major companies in the bioinformatics market are concentrating on developing advanced technological solutions, such as bioinformatics platforms, to enhance data analysis capabilities, improve accuracy in personalized medicine, and speed up drug discovery processes. A bioinformatics platform is a software system or integrated set of tools designed to manage, analyze, and interpret biological data, including genomic, proteomic, and metabolomic information, to support research and clinical decision-making. For example, in February 2024, Metabolon, Inc., a US-based biotechnology company, launched an integrated bioinformatics platform. This platform provides a comprehensive suite of analytical tools aimed at streamlining metabolomics research, allowing users to perform complex analyses with ease. Key features include advanced visualization tools such as volcano plots and principal component analysis (PCA), along with the innovative biomarker lenses, which deliver targeted insights into specific pathways and diseases.

In October 2024, Certara, a US-based provider of model-informed drug development, biosimulation software, and scientific informatics solutions, acquired Chemaxon for US$90 million in cash. Through this acquisition, Certara aims to strengthen its in silico drug discovery and development capabilities by integrating Chemaxon’s cheminformatics and bioinformatics tools with Certara’s biosimulation and AI-driven platforms. Chemaxon is a Hungary-based provider of cheminformatics and bioinformatics software, offering molecular modeling, chemical data management, and compound design tools for life sciences research.

Major companies operating in the bioinformatics market are Agilent Technologies Inc., Illumina Inc., QIAGEN NV, Affymetrix Inc., Thermo Fisher Scientific Inc., BGI Group, Dassault Systems SE, Bruker Corporation, Biomax Informatix AG, DNASTAR Inc., Partek Inc., Geneva Bioinformatics SA, Accelrys Inc., Nonlinear Dynamics SA, Sophia Genetics SA, Celera Corporation, Tripos Inc., IBM Life Sciences, GNS Healthcare Inc., DNAnexus Inc., Syapse Inc.

North America was the largest region in the bioinformatics market in 2025. Western Europe was the second largest region in the bioinformatics market analysis. The regions covered in the bioinformatics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioinformatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bioinformatics market by increasing costs of imported high-performance computing hardware, data storage systems, networking equipment, and specialized software licenses. Research institutions, pharmaceutical companies, and genomics service providers in North America and Europe are most affected due to dependence on imported computing infrastructure, while Asia-Pacific faces higher costs for platform exports. These tariffs are raising operational expenses and slowing infrastructure upgrades. However, they are also encouraging local data center development, regional software innovation, and increased adoption of open-source bioinformatics solutions.

The bioinformatics market research report is one of a series of new reports that provides bioinformatics market statistics, including bioinformatics industry global market size, regional shares, competitors with a bioinformatics market share, detailed bioinformatics market segments, market trends and opportunities, and any further data you may need to thrive in the bioinformatics industry. This bioinformatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioinformatics, related to genetics and genomics, utilizes computer technology to collect, store, analyze, and share biological data and information, including DNA and amino acid sequences or annotations associated with those sequences.

The primary products and services in bioinformatics include knowledge management tools, data analysis platforms, and services. Knowledge management tools are technologies that enable organizations to share information internally as well as externally. Their applications encompass metabolomics, molecular phylogenetics, transcriptomics, proteomics, chemoinformatics, genomics, and more, which are utilized by pharmaceuticals, animal research, agriculture, forensic science, and other end users.

The bioinformatics market includes revenues earned by entities by providing solutions which combine computer programming, information engineering, mathematics, and statistics to analyze biological data for drug discovery and preclinical studies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.